Company intelligence / Profile preview
Innocan Pharma Corporation
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has received positive feedback from the FDA following a pre-IND Type B meeting for their LPT-CBD technology. They have conducted pre-clinical trials showing significant pain relief in companion dogs with osteoarthritis. The FDA's Center for Veterinary Medicine has granted a fee waiver and assigned an Investigational New Animal Drug number for their LPT-CBD product[3][5].
- Therapeutic areas
- RheumatologyNeurology
- Modalities
- Liposomal drug deliverySmall moleculesCannabidiol (CBD)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaboration with Hebrew University in Jerusalem[5]
Beyond the preview
Go deeper on Innocan Pharma Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innocan Pharma Corporation.